Driven by sales of the S9 AutoSet and VPAP Adapt SV flow generators along with strong interface sales, ResMed posted record growth for the quarter ended September 30, 2011.
“Patient interface sales continue to perform strongly in all regions,” said Peter C. Farrell, PhD, chairman and CEO of ResMed. “Worldwide, our growth in flow generators was mainly driven by sales of the S9 AutoSet and VPAP Adapt SV.”
Revenue for the quarter ended September 30, 2011, was a record $314.8 million, a 12% increase over the quarter ended September 30, 2010.
Increased awareness and growing research linking sleep-disordered breathing to other disease states have led to favorable market conditions for the company.
“At the Congress of the World Sleep Federation, in Kyoto, Japan, the connection between sleep-disordered breathing and both heart failure and type 2 diabetes mellitus was highlighted, with particular emphasis on the need to address sleep-disordered breathing diagnosis and treatment for patients with type 2 diabetes,” Farrell said. “In fact, both Japanese cardiologists and endocrinologists are initiating their own sleep studies to simplify the diagnostic procedures for sleep-disordered breathing.”
Furthermore, according to Farrell, “ResMed has recently begun an initiative to engage existing patients by lowering the emotional barriers to therapy through an exclusive arrangement with Skinit for our CPAP devices. Skins can provide a unique opportunity to connect patients personally with their machine early in the process, reconnect with patients who have abandoned therapy, and provide an accessories revenue stream for the home care dealer."